LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, today announced its cash position and its turnover for the first half 2016.
As of June 30th, 2016, cash and cash equivalents were €32.1 million compared to €29.5 million on June 30th, 2015.
As expected, Poxel did not generate revenues in the first half of 2016.
These figures are consistent with the Company’s expectations and its growth strategy, which remains focused on the clinical development of its diabetes drug candidates Imeglimin and PXL770.
Next financial press release: First half financial results and corporate update, September 12th, 2016.
About Poxel
Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of type 2 diabetes. We have successfully completed our Phase 2 trials for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S. and EU and have entered Phase 2b clinical development in Japanese patients. We are advancing our second program, PXL770, a direct AMPK activator, which is in Phase 1 development. We intend to generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxel.com)
View source version on businesswire.com: http://www.businesswire.com/news/home/20160712006241/en/
Poxel SA
Jonae R. Barnes, +1 617-818-2985
Senior
Vice President, Investor Relations and Public Relations
jonae.barnes@poxelpharma.com
or
Investor
relations / Media - EU/US
MacDougall Biomedical Communications
Gretchen
Schweitzer, + 49 89 2424 3494
or
Stephanie May, + 49 175 571
1562
smay@macbiocom.com
or
Investor
relations / Media - France
NewCap
Florent Alba/Nicolas
Mérigeau, + 33 1 44 71 98 55
poxel@newcap.fr
Source: Poxel SA
Released July 12, 2016